Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
3.140
-0.110 (-3.38%)
At close: Aug 13, 2025, 4:00 PM
3.150
+0.010 (0.32%)
Pre-market: Aug 14, 2025, 8:38 AM EDT
Skye Bioscience Employees
Skye Bioscience had 16 employees as of December 31, 2024. The number of employees increased by 5 or 45.45% compared to the previous year.
Employees
16
Change (1Y)
5
Growth (1Y)
45.45%
Revenue / Employee
n/a
Profits / Employee
-$2,648,310
Market Cap
97.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SKYE News
- 6 days ago - Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 15 days ago - Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 - GlobeNewsWire
- 5 weeks ago - Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing - Seeking Alpha
- 7 weeks ago - Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 2 months ago - Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 3 months ago - Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewsWire
- 3 months ago - Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab - GlobeNewsWire